arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

VYNE Therapeutics Inc.

VYNE

$28.05 0.00 (0.00%) at close

12 Visible periods

31 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Moderately Bearish

auto_awesome

Analytical Summary

VYNE Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $1.2B

Dividend Yield —

Revenue Growth 13.8% ↘

Op. Margin None

ROIC -107.2% ↘

FCF / Share $-0.77 ↗

Trailing P/E —

Price / Book 33.7x

FCF Yield —

Debt / Equity 0.00

info Valuation on last close. End-of-day price, Jul 27, 2026.

12-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$570.00K

↑ +13.8% —

Net Income Profit after all expenses

$-26.48M

↑ +33.5% —

FCF / Share Free cash flow per share

$-0.77

↑ +2.9% —

Long-Term Debt Long-term obligations

$0.00

— —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Financial Health

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Revenue Growth YoY (%)	13.8% Good ↑ Good Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+72%)	18.2% Good ↑ Good Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+127%)	-11.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-239%)	-96.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1310%)	-29.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-471%)	4638.8% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+57885%)	-95.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1298%)	132.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1553%)	—	—	—	—
EPS Growth YoY (%)	33.3% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	66.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	61.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	-82.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	33.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-40.0% Weak ↓ Weak Declining Year-over-year change in net income	-22.6% Weak ↓ Weak Declining Year-over-year change in net income	68.3% Excellent ↑ Excellent Improving Year-over-year change in net income	71.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-168.5% Weak ↓ Weak Declining Year-over-year change in net income	-85.0% Weak ↑ Weak Improving Year-over-year change in net income	-76.9% Weak ↑ Weak Improving Year-over-year change in net income	-106.7% Weak Weak Year-over-year change in net income	-205.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	2.9% Caution ↓ Caution Declining Year-over-year change in free cash flow	67.7% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	73.1% Excellent Excellent Year-over-year change in free cash flow	97.4% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	6.1% Fair ↑ Fair Improving Compound annual revenue growth over 3 years	-67.6% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-72.8% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	2.5% Caution ↓ Caution Declining Compound annual revenue growth over 3 years	11.5% Good Good Compound annual revenue growth over 3 years	66.1% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—
Revenue CAGR 5Y (%)	-51.4% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	2.5% Caution ↑ Caution Improving Compound annual revenue growth over 5 years	-47.5% Weak Weak Compound annual revenue growth over 5 years	-36.4% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Operating Margin (%) (%)	—	—	—	—	-461.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3174%)	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.6% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
Profit Margin (%) (%)	—	—	—	—	-497.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4241%)	—	—	-483.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4129%)	—	—	—	—
FCF Margin (%) (%)	—	—	—	—	-382.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	-496.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	1.25x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.26x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.54x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.17x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Return on Invested Capital (%)	-107.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-83.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-33.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-110.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-139.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-357.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-190.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-33.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	41.0% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	38.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	22.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-98.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-65.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-30.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-84.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-101.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-269.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-118.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-39.0% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-44.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-34.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-95.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-736%)	-76.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-610%)	-32.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-314%)	-74.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-596%)	-150.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1105%)	—	—	-39.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-363%)	51.0% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+240%)	47.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+219%)	28.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+93%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Debt to Equity (x)	0.00x Excellent → Excellent Stable Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.00x Excellent → Excellent Stable Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.88x Fair Fair Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+47%)	1.86x Weak Weak Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+210%)	—	—	—	—	—
Interest Coverage (x)	—	—	—	—	-12.13x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-57.53x Weak Weak Operating income divided by interest expense Optimal: > 5x	-104.10x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—
Net Debt (USD)	$-24.03M	$-19.93M	$-30.62M	$-30.91M	$-42.25M	$-24.39M	$-11.03M	$-49.51M	$-10.21M	$-4.03M	$-43.81M	$-273.00K
Debt / EBITDA (x)	0.00x Excellent → Excellent Stable Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent → Excellent Stable Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.13x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.34x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Revenue per Share (USD)	$0.01	$0.01	$0.04	$0.15	$92.90	$209.86	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.62	$-0.93	$-2.78	$-7.28	$460.17	$2.55K	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.77	$-0.80	$-2.47	$-9.17	$-354.90	—	—	—	—	—	—	—
Book Value per Share (USD)	$0.83	$3.51	$6.29	$9.66	$294.17	$281.22	$624.50	$7.27K	—	$-7.23K	—	—
Tangible Book Value per Share (USD)	$0.83	$3.51	$6.29	$9.66	$294.17	$281.22	$624.50	$7.27K	—	$-7.23K	—	—
Basic Weighted Avg Shares (shares)	42.77M	42.59M	10.27M	3.19M	158,823	100,035	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Working Capital (USD)	$27.61M	$49.62M	$88.42M	—	$44.78M	$65.49M	$47.09M	$129.96M	$56.04M	$27.64M	—	—
LT Debt (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$33.17M	$32.73M	—	—	—	—	—
Total Equity (USD)	$27.77M	$52.09M	$88.73M	$31.20M	$48.64M	$37.49M	$17.57M	$130.38M	$-57.03M	$-29.44M	$-15.95M	$-11.41M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Sales/Revenue/Turnover (USD)	$570.00K	$501.00K	$424.00K	$477.00K	$14.76M	$20.99M	$443.00K	$10.64M	$4.58M	—	—	—
Depreciation Expense (USD)	$23.00K	$4.00K	$0.00	$72.00K	$109.00K	$341.00K	$350.00K	—	—	—	—	—
Net Income, GAAP (USD)	$-26.48M	$-39.83M	$-28.45M	$-23.21M	$-73.33M	$-255.57M	$-95.18M	$-51.45M	$-29.08M	$-14.07M	$-4.61M	—
Operating Cash Flow (USD)	$-33.12M	$-33.97M	$-25.34M	$-29.20M	$-56.37M	$-137.08M	$-73.39M	$-52.73M	$-28.22M	$-2.29M	$-4.18M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 39 quarters

VYNE Therapeutics Inc.

Analytical Summary

12-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare VYNE with peers